New shares registered with Finnish Trade Register
Faron Pharmaceuticals Ltd. has registered 38,055,229 newly issued shares with the Finnish Trade Register, bringing the total registered shares to 157,527,889, with 41,743,928 shares in treasury, resulting in 115,783,961 voting rights. Following the settlement of all offer shares, the company will have 199,472,660 shares and 3,530,573 treasury shares, leading to 195,942,087 total voting rights. Applications have been made for the admission to trading of these new shares on Nasdaq First North Growth Market Finland and AIM, with trading expected to commence around April 14, 2026, for the cornerstone investors and guarantors, and around April 15, 2026, for the remaining offer shares.
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
| Faron Pharmaceuticals Ltd | Company announcement | April 10, 2026 at 15:55:00 EEST |
Faron Pharmaceuticals Ltd: New shares registered with Finnish Trade Register
TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON, “Faron” or the “Company”) announced yesterday results of the share offering (the “Offering“) consisting of 80,158,126 offer shares (the “Offer Shares”). Faron has today registered with the Trade Register maintained by the Patent and Registration Office 38,055,229 newly issued shares (“New Shares”), which were allocated to the cornerstone investors and guarantors, and which will be delivered against payment of the subscription price in full.
Following the completion of the registration, the total number of registered shares in Faron is 157,527,889. The Company has 41,743,928 shares in treasury and therefore, the total number of voting rights in Faron is 115,783,961. After all Offer Shares are registered and settled, the total number of shares in the Company will be 199,472,660 and the Company will have 3,530,573 treasury shares. Accordingly, following the settlement of all Offer Shares, the total number of voting rights in Faron will be 195,942,087. Offer Shares all together account for approximately 67.1 per cent of all the shares in the Company prior to the Offering.
As previously announced, the New Shares have been registered first as treasury shares of the Company and will be further conveyed to the cornerstone investors and guarantors with payment and settlement (delivery against payment of the subscription price in full) expected to be completed on or about 14 April 2026.
Applications have been made for the admission to trading of the New Shares on the Nasdaq First North Growth Market Finland (“First North“) maintained by Nasdaq Helsinki Ltd (“Nasdaq Helsinki“) under the current trading code “FARON”, and on AIM (“AIM“), the market of that name operated by London Stock Exchange plc under the trading code “FARN”. Trading in the New Shares is expected to commence on or around 10:00 a.m. EEST / 8:00 a.m. BST on 14 April 2026 subject to the admission of the New Shares to trading on First North and AIM.
The remaining Offer Shares are expected to be registered with the Finnish Trade Register on or about 14 April 2026 and recorded on investors' book-entry accounts on or about 15 April 2026. Trading in the remaining Offer Shares on First North and in the Offer DIs on AIM is expected to commence on First North and AIM on or about 15 April 2026 subject to the admission of the Offer Shares to trading on First North and AIM.
Faron Pharmaceuticals Ltd
About bexmarilimab
Caution regarding forward-looking statements
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.